Financial Incentives Seen As A Path To Resurgence Of Antibiotics
Executive Summary
As calls to develop novel antibiotics to treat drug-resistant bacteria grow louder, financial incentives remain a focus in the search for options to stimulate drug discovery
You may also be interested in...
Antibiotic Development Incentives Face Critical Test As NDA Reviews Begin
GAIN has encouraged FDA to be flexible on data requirements for antibiotics, according to sponsors.
Antibiotic Development Incentives Face Critical Test As NDA Reviews Begin
Law has encouraged FDA to be flexible on data requirements for antibiotics, according to sponsors.
Antibiotics For Drug-Resistant Infections Hope To Skip Phase III Trials
PhRMA working group lays out proposal to allow approval of antibiotics for infections constituting an unmet medical need based on open-label studies and observational data.